An Open Label Phase I Study of Gemcitabine/Oxaliplatin (GEMOX) and Vandetanib (ZACTIMA; ZD6474) Combination in Patients With Advanced Solid Malignancy (IRUSZACT0070) (UPCI 07-025).
Phase of Trial: Phase I
Latest Information Update: 24 Jan 2014
At a glance
- Drugs Vandetanib (Primary) ; Gemcitabine; Oxaliplatin
- Indications Solid tumours
- Focus Adverse reactions
- 21 Jan 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 17 Jan 2013 Planned end date changed from 1 Oct 2012 to 1 Oct 2013 as reported by ClinicalTrials.gov.
- 28 Apr 2011 Planned end date changed from 1 Oct 2010 to 1 Oct 2012 as reported by ClinicalTrials.gov.